This biotechnology company specializes in the cultivation and development of high-quality medicinal cannabis products, utilizing advanced agricultural techniques and genetic research to enhance therapeutic efficacy. By providing pharmaceutical companies with reliable access to standardized cannabis-derived compounds, the company facilitates the discovery of new drugs and improves treatment options for patients.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Access to consistent, high-quality medicinal cannabis products can be challenging for pharmaceutical companies and patients due to variations in plant quality, safety concerns, and a lack of standardized formulations. Practitioners also face difficulties in prescribing due to limited data and analytics supporting the effectiveness of specific cannabis-derived medicines.
Solution
Medibis addresses these challenges by focusing on the cultivation, research, and delivery of cannabinoid-based therapies. The company utilizes advanced agricultural techniques and genetic research to develop cannabis plants with strong expressions of cannabinoids, flavonoids, and terpenoids, while ensuring they are free from impurities, heavy metals, and unsafe microbial content. Medibis develops unique phenotypes under laboratory conditions and employs breeding techniques to further improve them. By applying data and analytics, Medibis establishes an evidence base for its medicines, providing practitioners with the information needed to prescribe effectively and confidently. The company aims to provide a stable and sustainable platform for developing cannabis into various derivatives and Active Pharmaceutical Ingredients (APIs).
Target Audience
Medibis primarily serves pharmaceutical companies seeking reliable access to standardized cannabis-derived compounds, as well as patients requiring medicinal cannabis and practitioners prescribing cannabis-based treatments.
Features
- Cultivation under clean conditions to ensure products are free from impurities, heavy metals, toxins, and unsafe microbial content.
- Genotype selection based on effectiveness for specific conditions, developed into unique phenotypes under laboratory conditions.
- Data and analytics used to establish an evidence base for medicines, supporting practitioners in prescribing.
- Focus on strong expressions of cannabinoids, flavonoids, and terpenoids without using any nasty chemicals.
- Oil and dried flower products manufactured in Australia.
- Investment in research of the endocannabinoid system's interaction with medicinal cannabis.